Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion ...

Technology will soon make it possible to develop cheap, widely accessible psychoactive substances that are not harmful in the ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes ...

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Trump’s “big beautiful” bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of ...

One of the best known communications executives in corporate America, Susman worked at Pfizer for nearly two decades after ...

There are several successful investing strategies in the stock market and one of them is Dogs of the Dow. It is a strategy ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...